Age Distribution of the Patients;Body Temperature Means of the Patients;Changes in Oxygen Saturation (SpO2) Values;Changes in Serum D-dimer Levels;Changes in Serum Ferritin Levels;Changes in Serum Lymphocyte Counts;Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2);Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L);Gender Distribution of the Patients;Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism;Heart Rate Means of the Patients;Number of Participants With Clinical Response;Percentage of Patients With Accompanying Diseases;Percentage of Patients With Baseline Clinical Symptoms;Respiratory Rate Means of the Patients;Systolic and Diastolic Pressure Means of the Patients;Treatment-Related Adverse Events as Assessed by CTCAE v4.0

Age Distribution of the Patients;Body Temperature Means of the Patients;Changes in Oxygen Saturation (SpO2) Values;Changes in Serum D-dimer Levels;Changes in Serum Ferritin Levels;Changes in Serum Lymphocyte Counts;Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2);Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L);Gender Distribution of the Patients;Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism;Heart Rate Means of the Patients;Number of Participants With Clinical Response;Percentage of Patients With Accompanying Diseases;Percentage of Patients With Baseline Clinical Symptoms;Respiratory Rate Means of the Patients;Systolic and Diastolic Pressure Means of the Patients;Treatment-Related Adverse Events as Assessed by CTCAE v4.0

Changes in the ratio of partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) (PaO2/FiO2);Changes in serum ferritin levels;Changes in the ratio of polymorphonuclear leukocyte count to lymphocyte count (PNL/L);Changes in serum D-dimer levels;Changes in serum lymphocyte counts;Gender distribution of the patients;Clinical response;Systolic and diastolic pressure means of the patients;Genetic examination of haplotypes and mutations that cause function losing for ivermectin metabolism;Treatment-Related Adverse Events as Assessed by CTCAE v4.0;Percentage of patients with accompanying diseases;Percentage of patients with baseline clinical symptoms;Age distribution of the patients;Body temperature means of the patients;Heart rate means of the patients;Changes in oxygen saturation (SpO2) values;Respiratory rate means of the patients

Changes in the ratio of partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) (PaO2/FiO2);Changes in serum ferritin levels;Changes in the ratio of polymorphonuclear leukocyte count to lymphocyte count (PNL/L);Changes in serum D-dimer levels;Changes in serum lymphocyte counts;Gender distribution of the patients;Clinical response;Systolic and diastolic pressure means of the patients;Genetic examination of haplotypes and mutations that cause function losing for ivermectin metabolism;Treatment-Related Adverse Events as Assessed by CTCAE v4.0;Percentage of patients with accompanying diseases;Percentage of patients with baseline clinical symptoms;Age distribution of the patients;Body temperature means of the patients;Heart rate means of the patients;Changes in oxygen saturation (SpO2) values;Respiratory rate means of the patients